The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity

Aomatsu, 2010, Fulminant hepatitis B and acute hepatitis B due to intrafamilial transmission of HBV after chemotherapy for non-Hodgkin's lymphoma in an HBV carrier, Eur. J. Pediatr., 169, 167, 10.1007/s00431-009-1000-6 Apetoh, 2007, Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nat. Med., 13, 1050, 10.1038/nm1622 Arnould, 2006, Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?, Br. J. Cancer, 94, 259, 10.1038/sj.bjc.6602930 Burgdorf, 2008, Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation, Nat. Immunol., 9, 558, 10.1038/ni.1601 Chen, 2009, CD24 and Siglec-10 selectively repress tissue damage-induced immune responses, Science, 323, 1722, 10.1126/science.1168988 Clynes, 2000, Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets, Nat. Med., 6, 443, 10.1038/74704 Dhodapkar, 2002, Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells, J. Exp. Med., 195, 125, 10.1084/jem.20011097 Emens, 2001, Chemotherapy: friend or foe to cancer vaccines?, Curr. Opin. Mol. Ther., 3, 77 Fan, 2006, NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors, Blood, 107, 1342, 10.1182/blood-2005-08-3485 Gennari, 2004, Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2, Clin. Cancer Res., 10, 5650, 10.1158/1078-0432.CCR-04-0225 Hudis, 2007, Trastuzumab—mechanism of action and use in clinical practice, N. Engl. J. Med., 357, 39, 10.1056/NEJMra043186 Ishihara, 2004, HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2+ cancer patients, Int. J. Oncol., 24, 967 Jacob, 2006, Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice, Cell. Immunol., 240, 96, 10.1016/j.cellimm.2006.07.002 Kalergis, 2002, Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells, J. Exp. Med., 195, 1653, 10.1084/jem.20020338 Kiessling, 2002, Cellular immunity to the Her-2/neu protooncogene, Adv. Cancer Res., 85, 101, 10.1016/S0065-230X(02)85004-7 Kim, 2007, Adaptive immune cells temper initial innate responses, Nat. Med., 13, 1248, 10.1038/nm1633 Le, 2005, Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling, J. Biol. Chem., 280, 2092, 10.1074/jbc.M403080200 Lee, 2009, Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment, Blood, 114, 589, 10.1182/blood-2009-02-206870 Liao, 2006, Synchrony of high endothelial venules and lymphatic vessels revealed by immunization, J. Immunol., 177, 3369, 10.4049/jimmunol.177.5.3369 Machiels, 2001, Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice, Cancer Res., 61, 3689 Meric-Bernstam, 2006, Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy, Clin. Cancer Res., 12, 6326, 10.1158/1078-0432.CCR-06-1732 Mittendorf, 2010, A novel interaction between HER2/neu and cyclin E in breast cancer, Oncogene, 29, 3896, 10.1038/onc.2010.151 Moasser, 2007, Targeting the function of the HER2 oncogene in human cancer therapeutics, Oncogene, 26, 6577, 10.1038/sj.onc.1210478 Montgomery, 2005, Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase, Cancer Res., 65, 650, 10.1158/0008-5472.650.65.2 Musolino, 2008, Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer, J. Clin. Oncol., 26, 1789, 10.1200/JCO.2007.14.8957 Park, 2008, Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine, Cancer Res., 68, 1979, 10.1158/0008-5472.CAN-07-5688 Pegram, 1999, Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers, Oncogene, 18, 2241, 10.1038/sj.onc.1202526 Pegram, 2004, Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer, J. Natl. Cancer Inst., 96, 739, 10.1093/jnci/djh131 Piccart-Gebhart, 2005, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N. Engl. J. Med., 353, 1659, 10.1056/NEJMoa052306 Rafiq, 2002, Immune complex-mediated antigen presentation induces tumor immunity, J. Clin. Invest., 110, 71, 10.1172/JCI0215640 Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N. Engl. J. Med., 353, 1673, 10.1056/NEJMoa052122 Rovero, 2000, DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice, J. Immunol., 165, 5133, 10.4049/jimmunol.165.9.5133 Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Stagg, 2008, Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response, Proc. Natl. Acad. Sci. USA, 105, 16254, 10.1073/pnas.0806849105 Taylor, 2007, Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy, Clin. Cancer Res., 13, 5133, 10.1158/1078-0432.CCR-07-0507 Urbonaviciute, 2008, Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE, J. Exp. Med., 205, 3007, 10.1084/jem.20081165 Varchetta, 2007, Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2, Cancer Res., 67, 11991, 10.1158/0008-5472.CAN-07-2068 Wang, 2005, Stimulating lymphotoxin beta receptor on the dendritic cells is critical for their homeostasis and expansion, J. Immunol., 175, 6997, 10.4049/jimmunol.175.10.6997 Wei, 2005, Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice, Cancer Res., 65, 8471, 10.1158/0008-5472.CAN-05-0934 Whittington, 2008, DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies, Cancer Res., 68, 7502, 10.1158/0008-5472.CAN-08-1489 Yu, 2004, Priming of naive T cells inside tumors leads to eradication of established tumors, Nat. Immunol., 5, 141, 10.1038/ni1029 Yu, 2007, Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases, J. Immunol., 179, 1960, 10.4049/jimmunol.179.3.1960 Zhang, 1999, Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies, Exp. Mol. Pathol., 67, 15, 10.1006/exmp.1999.2266